With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.23462-75-1,Dihydro-2H-pyran-3(4H)-one,as a common compound, the synthetic route is as follows.
[01 77j Synthesis of ethyl 6,7-dihydro-5H-thieno [3 ,2-b]pyran-2-carboxylatewas similar to that of ethyl 6,7-dihydro-4H-thieno[3,2-c]pyran-2-carboxylate in Example 3, except dihydro-2H- pyran-3(4H)-one was substituted for dihydro-2H-pyran-4(3H)-one. The residue was purified by column chromatography (silica, petroleum ether/EtOAc = 8:1) to give product ethyl 6,7-dihydro- 5H-thieno[3,2-b]pyran-2-carboxylate (319 mg, yield: 30%) as a white liquid. ESI-MS (M+H):213.1. ?H NMR (400 MHz, CDC13) (5: 7.26 (s, 1H), 4.31 (q, J = 7.2 Hz, 2H), 4.17 (t, J = 5.2 Hz, 2H), 2.79 (t, J = 6.8 Hz, 2H), 2.08-2.02 (m, 2 H), 1.35 (t, J = 6.8 Hz, 3H).
23462-75-1, 23462-75-1 Dihydro-2H-pyran-3(4H)-one 90109, aTetrahydropyrans compound, is more and more widely used in various fields.
Reference£º
Patent; BIOGEN IDEC MA INC.; SUNESIS PHARMACEUTICALS, INC.; HOPKINS, Brian, T.; MA, Bin; CHAN, Timothy, Raymond; SUN, Lihong; ZHANG, Lei; KUMARAVEL, Gnanasambandam; LYSSIKATOS, Joseph, P.; KOCH, Kevin; MIAO, Hua; WO2015/89337; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics